Form 4: Amicus Therapeutics Executive David Michael Clark Reports Stock Transactions

Amicus Therapeutics' Chief People Officer, David Michael Clark, reported multiple transactions involving company stock, including the acquisition of restricted stock units and stock options.

Summary

• David Michael Clark, Chief People Officer at Amicus Therapeutics, reported several transactions involving the company's stock.
• On January 2, 2025, 5,381 shares were disposed of at a price of $9.31 per share.
• On January 3, 2025, 69,228 shares were acquired as restricted stock units (RSUs) at a price of $0, which will vest in four equal annual installments starting January 3, 2026.
• Also on January 3, 2025, 11,987 shares were disposed of at a price of $9.41 per share.
• On January 4, 2025, 2,692 shares were disposed of at a price of $9.41 per share.
• Additionally, on January 3, 2025, 125,430 stock options were acquired at a price of $0, vesting over four years with 25% vesting after one year and the remaining 75% vesting monthly thereafter.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of stock transactions by an executive, which is neither particularly positive nor negative. It is a standard practice and does not indicate any significant change in the company's outlook.

Positives

• The acquisition of 69,228 restricted stock units (RSUs) indicates a long-term commitment by the executive to the company's success.
• The acquisition of 125,430 stock options provides an incentive for the executive to contribute to the company's growth.

Negatives

• The disposal of 19,060 shares may be seen as a slight negative, although it is a small percentage of the total holdings.

Risks

• The vesting schedule of the RSUs and stock options could influence the executive's decisions regarding their tenure with the company.
• The market price of the stock could fluctuate, impacting the value of the RSUs and stock options.

Future Outlook

The restricted stock units will vest in four equal annual installments beginning on January 3, 2026, and the stock options will vest over a four-year period, which may influence the executive's long-term commitment to the company.

Industry Context

This filing is a routine disclosure of stock transactions by a company executive, which is common in publicly traded companies. It provides transparency into the executive's holdings and incentives.

Comparison to Industry Standards

• Stock option and restricted stock unit grants are standard forms of executive compensation in the biotechnology industry, used to align management's interests with those of shareholders.
• The vesting schedules of four years for both RSUs and stock options are typical for executive compensation packages.
• The reported transactions are consistent with standard practices for insider trading disclosures.

Stakeholder Impact

• The transactions provide transparency to shareholders regarding executive stock ownership.
• The vesting schedules of the RSUs and stock options may incentivize the executive to contribute to the company's long-term success.

Key Dates

Keywords

Amicus Therapeutics, stock transactions, insider trading, restricted stock units, stock options, Form 4, executive compensation, David Michael Clark